Travere Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Travere Therapeutics, Inc.
A Phase III hit moves atrasentan a step closer to the market but the drug will have to sell very well to justify the billions Novartis paid for its originator.
The European Medicines Agency is this week due to decide whether to recommend pan-EU marketing authorization for a number of new products.
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Desert Gateway, Inc.
- Kyalin Biosciences, Inc.
- Manchester Pharmaceuticals LLC.
- Orphan Technologies Ltd.
- Retrophin, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.